Frailty and Cancer: Current Perspectives on Assessment and Monitoring

Goede, Valentin

doi:10.2147/cia.s365494

Cited by 44 publications

(13 citation statements)

References 115 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These patients may also have absolute or relative contraindications for such procedures, including patient refusal, coagulation disorders, receiving anticoagulation treatment, and severe frailty. 41 , 42 This is particularly important since cancer patients are commonly on anticoagulants and/or may be too frail. These factors could make sympathetic block or other interventions more challenging and, if the pain is sympathetically independent, potentially less or not effective.…”

Section: Discussionmentioning

confidence: 99%

Complex Regional Pain Syndrome in Cancer Cases: Current Knowledge and Perspectives

Thanaboriboon,

Matos Macêdo,

Perez

2024

IMCRJ

View full text Add to dashboard Cite

Background Complex regional pain syndrome (CRPS) is a disabling painful disorder caused by many different and poorly understood mechanisms. It often affects the distal limbs and usually happens as consequence of a trauma. Its severity can remarkably affect patients’ quality of life. When this painful complication happens in a cancer patient, the impact may be exponential. To date, there is limited knowledge of the surrounding circumstances of CRPS cases in this population. Methods We present two clinical cases of patients diagnosed with cancer-related pain presenting with symptoms and signs compatible with CRPS. In one case, CRPS was attributed to direct tumor nerve compression, and it responded successfully to an interventional pain procedure. The second case was associated with a Zoster infection in an immunocompromised cancer patient. Patient responded to multidisciplinary pain management strategies. Additionally, we conducted a literature review to investigate the coexistence of cancer pain and CRPS and suggest some pathophysiology mechanisms of action. Results and Discussion Literature reviewed and potential pathophysiology mechanisms are simultaneously explored in terms of classification, etiopathology, evidence, challenges, and future scientific directions. Conclusion Comorbid CRPS can impact negatively in cases of cancer pain by affecting their diagnosis and treatment. Further studies are necessary to elucidate how these two conditions present together and how they can be better addressed.

show abstract

Section: Discussionmentioning

confidence: 99%

Complex Regional Pain Syndrome in Cancer Cases: Current Knowledge and Perspectives

Thanaboriboon,

Matos Macêdo,

Perez

2024

IMCRJ

View full text Add to dashboard Cite

show abstract

“…These characteristics are known to contribute negatively to treatment outcomes and may be of particular importance in MM. 22 , 23 For disparities between sexes, it has been shown that the incidence of MM is higher in males than females, but females still undergo higher frequency of autologous stem cell transplantation. 24 As we noted for age, this is likely multifactorial with biologic and behavioral components.…”

Section: Discussionmentioning

confidence: 99%

Impact of race and ethnicity on early mortality in multiple myeloma: a SEER analysis

Wei,

Shastri,

Sica

et al. 2023

haematol

View full text Add to dashboard Cite

Over the past two decades, there have been significant advances in the treatment of multiple myeloma which has led to an improvement in overall survival (OS) (1,2). However, a notable proportion of patients continue to experience early mortality (EM), defined as two years from the time of diagnosis. This raises the possibility that improvements in myeloma survival have not extended equally to all groups. Using the latest data drawn from the Surveillance Epidemiology and End Results (SEER) database of patients in the United States spanning 2000-2019, we study impact of important sociodemographic factors on EM. Through regression modeling, we demonstrate that patients diagnosed from 2000-2005, of older age, male sex, and of certain racial minority status (non-Hispanic Black and Hispanic) have higher odds of EM. Of these factors, minority status contributed to worse 2-year overall survival as well. We evaluate whether income, as a surrogate to access to care, could potentially explain this finding, but find that race has a distinct relationship with EM that is not modified by income. This is further reinforced by subgroup analysis. After characterizing groups vulnerable to EM, we examine reasons for these disparities and potential avenues to address them.

show abstract

“…They concluded that a substantial reduction in muscle mass is predictive of decreased survival in patients undergoing palliative chemotherapy. Furthermore, frailty can increase from 13% to 43% following chemotherapy treatment [ 7 ]. Taken together, these data are relevant given that cachexia, sarcopenia, and frailty may negatively impact the quality of life and treatment outcomes for cancer patients [ 8 – 12 ].…”

Section: Introductionmentioning

confidence: 99%

Doxorubicin causes cachexia, sarcopenia, and frailty characteristics in mice

Cella,

Matos,

Marinello

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

While chemotherapy treatment can be lifesaving, it also has adverse effects that negatively impact the quality of life. To investigate the effects of doxorubicin chemotherapy on body weight loss, strength and muscle mass loss, and physical function impairments, all key markers of cachexia, sarcopenia, and frailty. Seventeen C57/BL/6 mice were allocated into groups. 1) Control (n = 7): mice were exposed to intraperitoneal (i.p.) injections of saline solution. 2) Dox (n = 10): mice were exposed to doxorubicin chemotherapy cycles (total dose of 18 mg/kg divided over 15 days). The body weight loss and decreased food intake were monitored to assess cachexia. To assess sarcopenia, we measured muscle strength loss using a traction method and evaluated muscle atrophy through histology of the gastrocnemius muscle. To evaluate physical function impairments and assess frailty, we employed the open field test to measure exploratory capacity. Doxorubicin administration led to the development of cachexia, as evidenced by a significant body weight loss (13%) and a substantial decrease in food intake (34%) over a 15-day period. Furthermore, 90% of the mice treated with doxorubicin exhibited sarcopenia, characterized by a 20% reduction in traction strength (p<0,05), a 10% decrease in muscle mass, and a 33% reduction in locomotor activity. Importantly, all mice subjected to doxorubicin treatment were considered frail based on the evaluation of their overall condition and functional impairments. The proposed model holds significant characteristics of human chemotherapy treatment and can be useful to understand the intricate relationship between chemotherapy, cachexia, sarcopenia, and frailty.

show abstract

Frailty and Cancer: Current Perspectives on Assessment and Monitoring

Cited by 44 publications

References 115 publications

Complex Regional Pain Syndrome in Cancer Cases: Current Knowledge and Perspectives

Complex Regional Pain Syndrome in Cancer Cases: Current Knowledge and Perspectives

Impact of race and ethnicity on early mortality in multiple myeloma: a SEER analysis

Doxorubicin causes cachexia, sarcopenia, and frailty characteristics in mice

Contact Info

Product

Resources

About